Trong Hieu Nguyen
Overview
Explore the profile of Trong Hieu Nguyen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nguyen L, Nguyen T, Le V, Bui V, Nguyen L, Pham N, et al.
BMC Med
. 2025 Feb;
23(1):90.
PMID: 39948555
Background: Non-invasive multi-cancer early detection (MCED) tests have shown promise in enhancing early cancer detection. However, their clinical utility across diverse populations remains underexplored, limiting their routine implementation. This study...
2.
Nguyen T, Vu G, Nguyen T, Nguyen T, Tran V, Vu L, et al.
Cancer Med
. 2025 Jan;
14(1):e70575.
PMID: 39748775
Background: Multi-cancer early detection (MCED) through a single blood test significantly advances cancer diagnosis. However, most MCED tests rely on a single type of biomarkers, leading to limited sensitivity, particularly...
3.
Thien Nguyen C, Nguyen T, Vo D, Van T, Nguyen G, Tran T, et al.
Future Oncol
. 2024 Oct;
21(1):105-115.
PMID: 39431470
Cancers lacking standard screening (LSS) options account for approximately 70% of cancer-related deaths due to late-stage diagnosis. Circulating tumor DNA (ctDNA) is a promising biomarker for multi-cancer early detection. We...
4.
Nguyen T, Doan N, Tran T, Huynh L, Doan P, Nguyen T, et al.
J Transl Med
. 2024 Jul;
22(1):618.
PMID: 38961476
Background: Cell free DNA (cfDNA)-based assays hold great potential in detecting early cancer signals yet determining the tissue-of-origin (TOO) for cancer signals remains a challenging task. Here, we investigated the...
5.
Nguyen V, Nguyen T, Doan N, Pham T, Nguyen G, Nguyen T, et al.
Elife
. 2023 Oct;
12.
PMID: 37819044
Despite their promise, circulating tumor DNA (ctDNA)-based assays for multi-cancer early detection face challenges in test performance, due mostly to the limited abundance of ctDNA and its inherent variability. To...
6.
Le D, Nguyen T, Takasu F
J Theor Biol
. 2023 Jul;
572:111579.
PMID: 37454924
We revisit a spatial metapopulation model on continuous space as a stochastic point pattern dynamics. In the model, local patches as points are distributed with a certain spatial configuration and...
7.
Pham T, Phan T, Jasmine T, Tran T, Huynh L, Vo T, et al.
Front Oncol
. 2023 May;
13:1127086.
PMID: 37223690
Introduction: Breast cancer causes the most cancer-related death in women and is the costliest cancer in the US regarding medical service and prescription drug expenses. Breast cancer screening is recommended...
8.
Nguyen V, Nguyen T, Phan T, Tran T, Pham T, Ho T, et al.
BMC Cancer
. 2023 Mar;
23(1):233.
PMID: 36915069
Background: Late detection of hepatocellular carcinoma (HCC) results in an overall 5-year survival rate of less than 16%. Liquid biopsy (LB) assays based on detecting circulating tumor DNA (ctDNA) might...
9.
Nguyen T, Lu Y, Le V, Bui V, Nguyen L, Pham N, et al.
Cancer Invest
. 2023 Jan;
:1-17.
PMID: 36719061
The SPOT-MAS assay "Screening for the Presence Of Tumor by Methylation And Size" detects the five most common cancers in Vietnam by evaluating circulating tumor DNA in the blood. Here,...
10.
Nguyen H, Huynh L, Nguyen T, Tran D, Tran T, Le N, et al.
Future Oncol
. 2022 Dec;
18(35):3895-3912.
PMID: 36524960
Early detection of colorectal cancer (CRC) provides substantially better survival rates. This study aimed to develop a blood-based screening assay named SPOT-MAS ('screen for the presence of tumor by DNA...